instruction
stringlengths 33
156
| input
float64 | output
stringlengths 120
1.97k
|
---|---|---|
Does Abatacept and Aldesleukin interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Alectinib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Alectinib can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Alemtuzumab interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Alfentanil interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Alfentanil can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Allogeneic processed thymus tissue interact? | null | Allogeneic processed thymus tissue for immune reconstitution therapy aims to restore the immune function of patients with severe immunodeficiency caused by congenital athymia. The concomitant use of immunosuppressive agents may interfere with the therapeutic efficacy of immune reconstitution therapy. In short, The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Abatacept, and the severity of the interaction is minor. |
Does Abatacept and Almotriptan interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Almotriptan can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Alogliptin interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Alogliptin can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Alosetron interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Alosetron can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Alpelisib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Alpelisib can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Alprazolam interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Alprazolam can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Ambrisentan interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Ambrisentan can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Aminophylline interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates with a narrow therapeutic index. In short, The metabolism of Aminophylline can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Amiodarone interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C8 substrates with a narrow therapeutic index. In short, The metabolism of Amiodarone can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Amitriptyline interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates with a narrow therapeutic index. In short, The metabolism of Amitriptyline can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Amodiaquine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C8 substrates. In short, The metabolism of Amodiaquine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Amoxapine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates with a narrow therapeutic index. In short, The metabolism of Amoxapine can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Amphetamine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Amphetamine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Amsacrine interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Amsacrine is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Anagrelide interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates with a narrow therapeutic index. In short, The metabolism of Anagrelide can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Anakinra interact? | null | Anakinra may enhance the adverse effects of Abatacept and increase the risk of infection. A 2006 randomized controlled trial found that abatacept in combination with biologic background therapies was associated with an increase in the rate of serious adverse events and is therefore not recommended for use in combination with biologic therapy. The FDA recommends avoiding concurrent administration of abatacept with other biologic rheumatoid arthritis therapies, such as anakinra. However, a retrospective case series from 2011 of 4 patients with systemic juvenile idiopathic arthritis (sJIA) found this combination to be beneficial to patients with refractory sJIA, "allowing dose reduction of both anakinra and corticosteroids while improving arthritis joint count, as well as controlling systemic features of disease" . Further evidence is needed to confirm this case series and extrapolation to other patient demographics and disease states. In short, The risk or severity of adverse effects can be increased when Anakinra is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Anastrozole interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C8 substrates. In short, The metabolism of Anastrozole can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Anifrolumab interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Anifrolumab, and the severity of the interaction is major. |
Does Abatacept and Anthrax immune globulin human interact? | null | Vaccine efficacy may be reduced when immunosuppressant medications are coadministered. Vaccines are designed to elicit an immune response, and this response may be inhibited by immunosuppressants. The administration of live vaccines can also provide a risk as the infection process can be developed due to the immunosuppressive agent. In short, The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Anthrax vaccine interact? | null | Immunosuppressive therapies, including chemotherapy, corticosteroids (used in high-doses longer than 2 weeks), and radiation therapy may reduce the response of the anthrax vaccine BioThrax. In short, The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Abatacept, and the severity of the interaction is minor. |
Does Abatacept and Antilymphocyte immunoglobulin (horse) interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Antilymphocyte immunoglobulin (horse), and the severity of the interaction is major. |
Does Abatacept and Antipyrine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Antipyrine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Antithymocyte immunoglobulin (rabbit) interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Apalutamide interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C8 substrates. In short, The metabolism of Apalutamide can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Apixaban interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Apixaban can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Apomorphine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates. In short, The metabolism of Apomorphine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Apremilast interact? | null | The concomitant administration of apremilast with biologics for rheumatoid arthritis treatment has not been formally evaluated. Several studies have demonstrated that biologic agents frequently used in the treatment of psoriasis or rheumatoid arthritis may impact the metabolism of hepatic cytochrome enzyme substrates (such as apremilast) by stimulating cytochrome enzyme activities. Apremilast is a CYP3A4 substrate, and induction of this enzyme may lead to decreased therapeutic efficacy resulting from increased metabolism. In short, The therapeutic efficacy of Apremilast can be decreased when used in combination with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Aprepitant interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Aprepitant can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Arformoterol interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2A6 substrates. In short, The metabolism of Arformoterol can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Aripiprazole lauroxil interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Aripiprazole lauroxil can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Aripiprazole interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Aripiprazole can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Arsenic trioxide interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Asenapine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Asenapine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Astemizole interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates with a narrow therapeutic index. In short, The metabolism of Astemizole can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and AstraZeneca COVID-19 Vaccine interact? | null | Vaccine efficacy may be reduced when immunosuppressant medications are coadministered. Vaccines are designed to elicit an immune response, and this response may be inhibited by immunosuppressants. The administration of live vaccines can also provide a risk as the infection process can be developed due to the immunosuppressive agent. In short, The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Asunaprevir interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2A6 substrates. In short, The metabolism of Asunaprevir can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Atazanavir interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Atazanavir can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Atenolol interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Atenolol can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Atomoxetine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Atomoxetine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Atorvastatin interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A5 substrates. In short, The metabolism of Atorvastatin can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Avacopan interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Avacopan, and the severity of the interaction is major. |
Does Abatacept and Avanafil interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Avanafil can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Avapritinib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Avapritinib can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Avatrombopag interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Avatrombopag can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Axitinib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates with a narrow therapeutic index. In short, The metabolism of Axitinib can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Azacitidine interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Azacitidine is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Azathioprine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Azathioprine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Azelastine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Azelastine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Azithromycin interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates. In short, The metabolism of Azithromycin can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Bacillus calmette-guerin substrain russian BCG-I live antigen interact? | null | VERITY-BCG is a live BCG vaccine used in the treatment of bladder cancer. In order to exert its therapeutic effect, intravesically-administered live BCG vaccines require the development of an immune response - its coadministration with immunosuppressive agents, such as the subject drug, may therefore interfere with anti-tumor efficacy by dampening the desired immune response. In short, The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Bacillus calmette-guerin substrain tice live antigen interact? | null | In most cases, the coadministration of live vaccines and immunosuppressive agents is contraindicated due to the risk of uncontrolled replication of the virus and subsequent infection. Drugs capable of causing clinically significant immunosuppression include chemotherapeutic agents (e.g. alkylating agents, antimetabolites), high-dose corticosteroids, and immune mediators/modulators (e.g. TNF-alpha inhibitors). In short, The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Baricitinib interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Baricitinib, and the severity of the interaction is major. |
Does Abatacept and Basiliximab interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Basiliximab is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and BCG vaccine interact? | null | In most cases, the coadministration of live vaccines and immunosuppressive agents is contraindicated due to the risk of uncontrolled replication of the virus and subsequent infection. Drugs capable of causing clinically significant immunosuppression include chemotherapeutic agents (e.g. alkylating agents, antimetabolites), high-dose corticosteroids, and immune mediators/modulators (e.g. TNF-alpha inhibitors). In short, The risk or severity of infection can be increased when BCG vaccine is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Beclomethasone dipropionate interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Belatacept interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Belatacept, and the severity of the interaction is major. |
Does Abatacept and Belimumab interact? | null | Belimumab is a biologic treatment used for individuals with lupus 2, abatacept is also a biological treatment 1. While being studied, it was found that the use of abatacept with other biologic agents is not safe . The concurrent use of abatacept with another biologic agent may result in an increased incidence of serious infection and neoplasm, and the coadministration is therefore not advised . In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Belimumab, and the severity of the interaction is major. |
Does Abatacept and Belinostat interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Belinostat, and the severity of the interaction is major. |
Does Abatacept and Belumosudil interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Belumosudil, and the severity of the interaction is major. |
Does Abatacept and Belzutifan interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C19 substrates. In short, The metabolism of Belzutifan can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Bendamustine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates with a narrow therapeutic index. In short, The metabolism of Bendamustine can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Benzatropine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Benzatropine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Benzocaine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Benzocaine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Benzphetamine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates. In short, The metabolism of Benzphetamine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Benzyl alcohol interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Benzyl alcohol can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Betamethasone interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Betamethasone is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Betaxolol interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Betaxolol can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Bexarotene interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Bexarotene can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Bicalutamide interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Bicalutamide can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Bimekizumab interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Bimekizumab, and the severity of the interaction is major. |
Does Abatacept and Binimetinib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates with a narrow therapeutic index. In short, The metabolism of Binimetinib can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Bleomycin interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Bleomycin is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Blinatumomab interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Blinatumomab, and the severity of the interaction is major. |
Does Abatacept and Bortezomib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Bortezomib can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Bosentan interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Bosentan can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Bosutinib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Bosutinib can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Brentuximab vedotin interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Brentuximab vedotin can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Brexpiprazole interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Brexpiprazole can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Brigatinib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C8 substrates with a narrow therapeutic index. In short, The metabolism of Brigatinib can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Brivaracetam interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates. In short, The metabolism of Brivaracetam can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Brodalumab interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Brodalumab, and the severity of the interaction is major. |
Does Abatacept and Bromazepam interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Bromazepam can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Bromotheophylline interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Bromotheophylline can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Brompheniramine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates. In short, The metabolism of Brompheniramine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Budesonide interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Budesonide is combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Bupivacaine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Bupivacaine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Buprenorphine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Buprenorphine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Bupropion interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2B6 substrates. In short, The metabolism of Bupropion can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Buspirone interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2D6 substrates. In short, The metabolism of Buspirone can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Busulfan interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Busulfan can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Cabazitaxel interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Cabazitaxel can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Cabergoline interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP3A4 substrates with a narrow therapeutic index. In short, The metabolism of Cabergoline can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Cabozantinib interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates with a narrow therapeutic index. In short, The metabolism of Cabozantinib can be increased when combined with Abatacept, and the severity of the interaction is major. |
Does Abatacept and Caffeine interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP1A2 substrates. In short, The metabolism of Caffeine can be increased when combined with Abatacept, and the severity of the interaction is moderate. |
Does Abatacept and Canakinumab interact? | null | Immunosuppressive agents may exert an additive effect on other immunosuppressive agents, leading to a greater risk of infection due to bone marrow suppression. In short, The risk or severity of adverse effects can be increased when Abatacept is combined with Canakinumab, and the severity of the interaction is major. |
Does Abatacept and Candesartan cilexetil interact? | null | The formation of CYP450 enzymes is inhibited by the presence of increased levels of cytokines during chronic inflammation. Agents that reduce cytokine levels can normalize CYP450 formation and increase the metabolism of drugs. This interaction may significantly alter the therapeutic efficacy of CYP2C9 substrates. In short, The metabolism of Candesartan cilexetil can be increased when combined with Abatacept, and the severity of the interaction is moderate. |